Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 1A46 |
Synonyms | |
Therapy Description |
1A46 is a trispecific antibody that targets tumor-expressed CD19 and CD20, and T cell-expressed CD3, which potentially leads to an enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells expressing CD19 and CD20 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
1A46 | CMG1A46|CMG 1A46|CMG-1A46 | CD19 Antibody 21 CD20 Antibody 24 CD3 Antibody 99 | 1A46 is a trispecific antibody that targets tumor-expressed CD19 and CD20, and T cell-expressed CD3, which potentially leads to an enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells expressing CD19 and CD20 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05348889 | Phase Ib/II | 1A46 | First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies | Recruiting | USA | 0 |